HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target

Benzinga · 03/18 10:38
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $20 price target.